search
Back to results

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Primary Purpose

HIV Infections, Cytopenias

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Zidovudine
Sargramostim
Sponsored by
Sandoz
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring Leukopenia, Granulocyte-Macrophage Colony-Stimulating Factor, Acquired Immunodeficiency Syndrome, Zidovudine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Patients must have: Serum antibody to HIV with or without evidence of HIV antigenemia. White blood cells (WBC) = or < 4500 cells/mm3 measured on at least 2 occasions separated by a minimum of 1 week. Qualifying indications for AZT therapy. Life expectancy = or > 6 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Current or past history of malignancy including Kaposi's sarcoma. Excessive diarrhea or significant malabsorption. If patients have had > 10 percent weight loss within the past 3 months, they should not have malabsorption as evidenced by serum carotene < 75 IU/ml, serum vitamin A < 75 IU/ml, significant malabsorption 4 foul-smelling or greasy stools per day or other criteria. Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (IO). Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP). Active OI requiring systemic treatment. Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia. Concurrent Medication: Excluded within 4 weeks of study entry: Zidovudine (AZT). Other antiviral agent associated with leukopenia. Investigational drug. Immunomodulators. Interferon. Steroids. Excluded within 8 weeks of study entry: Ribavirin. Excluded within 4 months of study entry: Suramin. Patients with the following are excluded: Current or past history of malignancy including Kaposi's sarcoma. Excessive diarrhea or significant malabsorption. Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (OI). Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP). Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia. Prior Medication: Excluded: Prophylactic therapy for Pneumocystis carinii pneumonia (PCP) that may cause leukopenia. Risk Behavior: Excluded: Current drug or alcohol abusers. Unprotected sexual contact or other activities that may result in reinfection with HIV. Patients must be willing to refrain from unprotected sexual contact or other activities that may result in reinfection with HIV.

Sites / Locations

  • Natl Cancer Institute

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Sandoz
search

1. Study Identification

Unique Protocol Identification Number
NCT00002007
Brief Title
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
Official Title
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
Study Type
Interventional

2. Study Status

Record Verification Date
January 1990
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sandoz

4. Oversight

5. Study Description

Brief Summary
To evaluate the safety of repeated courses of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) administered subcutaneously to patients with HIV infection and leukopenia. To determine if administration of GM-CSF will prevent some or all of the hematologic toxicity associated with zidovudine ( AZT ) treatment in patients with pre-existing leukopenia. To assess any clinical and/or virologic benefits from administering alternating weeks of GM-CSF and AZT to patients with symptomatic HIV infection who have a history of cytologically confirmed Pneumocystis carinii pneumonia ( PCP ) or a circulating absolute CD4 lymphocyte count less than 200 cells/mm3.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, Cytopenias
Keywords
Leukopenia, Granulocyte-Macrophage Colony-Stimulating Factor, Acquired Immunodeficiency Syndrome, Zidovudine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Zidovudine
Intervention Type
Drug
Intervention Name(s)
Sargramostim

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Patients must have: Serum antibody to HIV with or without evidence of HIV antigenemia. White blood cells (WBC) = or < 4500 cells/mm3 measured on at least 2 occasions separated by a minimum of 1 week. Qualifying indications for AZT therapy. Life expectancy = or > 6 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Current or past history of malignancy including Kaposi's sarcoma. Excessive diarrhea or significant malabsorption. If patients have had > 10 percent weight loss within the past 3 months, they should not have malabsorption as evidenced by serum carotene < 75 IU/ml, serum vitamin A < 75 IU/ml, significant malabsorption 4 foul-smelling or greasy stools per day or other criteria. Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (IO). Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP). Active OI requiring systemic treatment. Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia. Concurrent Medication: Excluded within 4 weeks of study entry: Zidovudine (AZT). Other antiviral agent associated with leukopenia. Investigational drug. Immunomodulators. Interferon. Steroids. Excluded within 8 weeks of study entry: Ribavirin. Excluded within 4 months of study entry: Suramin. Patients with the following are excluded: Current or past history of malignancy including Kaposi's sarcoma. Excessive diarrhea or significant malabsorption. Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (OI). Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP). Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia. Prior Medication: Excluded: Prophylactic therapy for Pneumocystis carinii pneumonia (PCP) that may cause leukopenia. Risk Behavior: Excluded: Current drug or alcohol abusers. Unprotected sexual contact or other activities that may result in reinfection with HIV. Patients must be willing to refrain from unprotected sexual contact or other activities that may result in reinfection with HIV.
Facility Information:
Facility Name
Natl Cancer Institute
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

We'll reach out to this number within 24 hrs